Clinical Data Oruka surges as long-acting psoriasis drug shows early promise pharminent April 27, 2026
Clinical Data Cardiometabolic trials: Using expertise to turn complexity into robust results pharminent April 24, 2026
Clinical Data AAN 2026: J&J, Kyverna, Capricor and Praxis showcase practice-changing data pharminent April 23, 2026
Clinical Data Moderna, after losing US funding, rebounds to start mRNA bird flu vaccine trial pharminent April 22, 2026
Clinical Data Ionis’ antisense drug stabilizes ultra-rare disease ahead of FDA decision pharminent April 22, 2026
Clinical Data BioAge says early data suggest ‘best-in-class’ potential for inflammation drug pharminent April 21, 2026
Clinical Data Merck, Eisai’s Keytruda triplet fails to improve survival in kidney cancer pharminent April 21, 2026
Clinical Data AACR 2026: Moderna, Revolution, Zymeworks and BeOne showcase new data pharminent April 21, 2026
Clinical Data Gilead, Arcus tumble again in TIGIT, triggering 2 trial culls pharminent April 21, 2026
Clinical Data Nektar surges again as alopecia drug shows new promise in extension study pharminent April 20, 2026
Clinical Data Novo’s late-stage sickle cell win piles pressure on competitors pharminent April 20, 2026
Clinical Data Novo may have muscle advantage over Lilly in weight-loss race: preprint pharminent April 17, 2026
Clinical Data Lilly’s new obesity pill passes heart safety test in diabetes pharminent April 16, 2026
Clinical Data Lilly debuts more Foundayo data as FDA requests post-marketing trials pharminent April 16, 2026
Clinical Data Roche to start new Elevidys study following setback in Europe pharminent April 16, 2026
Clinical Data Lilly’s Foundayo posts ‘outstanding’ diabetes data, possibly easing FDA safety concerns pharminent April 16, 2026
Clinical Data Boehringer Ingelheim and Zai Lab team up for dual DLL3 therapy study pharminent April 16, 2026
Clinical Data Boehringer Ingelheim and Zai Lab team up for dual DLL3 therapy study pharminent April 16, 2026
Clinical Data S16 Ep52: Medical Crossfire: PD-L1 Inhibition in Advanced Cutaneous Squamous Cell Carcinoma — Mechanistic Rationale and Clinical Application pharminent April 15, 2026
Clinical Data Spyre drug for inflammatory bowel disease shows promise in early study pharminent April 13, 2026
Clinical Data Allogene data suggest ‘off-the-shelf’ CAR-T could delay relapse in lymphoma pharminent April 13, 2026
Clinical Data Allogene stock sails after CAR T clears residual lymphoma in early data cut pharminent April 13, 2026
Clinical Data Revolution rises 40% as pancreatic cancer drug doubles survival pharminent April 13, 2026
Clinical Data Amgen reports positive phase 3 results for subcutaneous TEPEZZA in thyroid eye disease pharminent April 7, 2026
Clinical Data CatalYm begins phase 2b trial of visugromab in second-line liver cancer treatment pharminent April 7, 2026
Clinical Data Sanofi Bispecific Scores in Asthma, Rhinosinusitis, but Eczema Bet Doesn’t Pay Off pharminent April 7, 2026
